Lipoprotein profile in limited systemic sclerosis

Rheumatology International

Volumn 25, Issue 5, 2005, Pages 379-383

  Borba, Eduardo F ^a   Borges, Claudia T L ^a   Bonfá, Eloísa ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Atherosclerosis; Dyslipoproteinemia; Lipoprotein; Risk factor; Systemic sclerosis

Indexed keywords

CENTROMERE ANTIBODY; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DEMOGRAPHY; DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; HIGH RISK POPULATION; HUMAN; LABORATORY TEST; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PULMONARY HYPERTENSION; RISK ASSESSMENT; SKIN DISEASE; STATISTICAL SIGNIFICANCE; SYSTEMIC SCLEROSIS;

ARTERIOSCLEROSIS; AUTOANTIBODIES; CENTROMERE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; FEMALE; HUMANS; LIPOPROTEINS; MIDDLE AGED; SCLERODERMA, LIMITED; TRIGLYCERIDES;

EID: 21544463151     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-004-0580-8     Document Type: Article

References (48)

1. Ross R (1999) Atherosclerosis - an inflammatory disease. N Engl J Med 340:115-126
2. Borba EF, Bonfá E (1997) Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 6:533-539
3. Borba EF, Bonfá E, Vinagre CGC, Ramires JAF, Maranhão RC (2000) Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum 43:1033-1040
4. Bruce IN, Gladman DD, Urowitz MB (2000) Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 26(2):257-278
5. Rantapää-Dahlqvist S, Wallberg-Jonsson S, Dahlen G (1991) Lipoprotein(a), lipids and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis 50:366-368
6. Lorber M, Aviram M, Linn S, Scharf Y, Brook JG (1985) Hypocholesterolemia and abnormal high-density lipoprotein in rheumatoid arthritis. Br J Rheumatol 24:250-255
7. Park YB, Lee SK, Lee WK et al (1999) Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 26:1701-1704
8. Carpentier H, Maricq HR (1990) Microvasculature in systemic sclerosis. Clin Exp Rheumatol 16:75-92
9. Kahaleh MB (1991) Endothelin, an endothelial-dependent vasoconstrictor in scleroderma: enhanced production and profibrotic action. Arthritis Rheum 34:978-983
10. Yamane K, Miyauchi T, Suzuki N et al (1992) Significance of plasma endothelin-1 levels in patients with SSc. J Rheumatol 19:1566-1571
11. Vancheeswaran R, Magoulas T, Efrat G, Penny RM, Black CM (1994) Circulating endothelin-1 levels in systemic sclerosis (SSc) subsets: a marker of fibrosis or vascular dysfunction? J Rheumatol 21:1838-1844
12. Kahaleh MB (1990) Vascular disease in scleroderma. Rheum Dis Clin North Am 16:53-73
13. Korn JH (1991) Immunological aspects of scleroderma. Curr Opin Rheumatol 3:947-952
14. Murrel DF (1993) A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol 28:78-85
15. Youssef P, Brama T, Englert H, Bertouch J (1995) Limited scleroderma is associated with increased prevalence of macrovascular disease. J Rheumatol 22:469-472
16. Veale DJ, Collidge TA, Belch JJF (1995) Increased prevalence of symptomatic macrovascular disease in systemic sclerosis. Ann Rheum Dis 54:853-855
17. Stafford L, Englert H, Gover J, Bertouch J (1998) Distribution of macrovascular disease in scleroderma. Ann Rheum Dis 57:476-479
18. Ho M, Veale D, Eastmond C, Nuki G, Belch J (2000) Macrovascular disease and systemic sclerosis. Ann Rheum Dis 59:39-43
19. Wan MC, Moore T, Hollis S, Herrick AL (2001) Ankle brachial pressure index in systemic sclerosis: influence of disease subtype and anticentromere antibody. Rheumatology 40:1102-1105
20. Dick EA, Aviv R, Francis I et al (2001) Catheter angiography and angioplasty in patients with scleroderma. Br J Radiol 74:1091-1096
21. LeRoy EC, Black C, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202-205
22. Siedel J, Hägele EO, Ziegenhorn J, Wahlefeld AW (1983) Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 29:1075-1080
23. Fossati P, Prencipe L (1982) Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 28:2077-2080
24. Warnick GR, Cheung MC, Albers JJ (1979) Comparison of current methods for high-density lipoprotein cholesterol quantification. Clin Chem 25:596-604
25. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502
26. Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486-2497
27. Kannel WB, Hjortland MC, McNamara PM, Gordon T (1976) Menopause and risk of cardiovascular disease. The Framingham study. Ann Intern Med 85:447-452
28. Denke MA, Sempos CT, Grundy SM (1994) Excess body weight. An under-recognized contributor to dyslipidemia in white American women. Arch Intern Med 154:401-410
29. Brown WV (1994) Lipoprotein disorders in diabetes mellitus. Med Clin North Am 78:143-161
30. Seidel D (1987) Lipoproteins in liver disease. J Clin Chem Clin Biochem 25:541-551
31. Thompson GR, Soutar AK, Spengel FA, Jadhav A, Gavigan SJP, Myant NB (1981) Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism. Proc Natl Acad Sci USA 78:2591-2595
32. Henkin Y, Como JA, Oberman A (1992) Secondary dyslipidemia. Inadvertent effects of drugs in clinical practice. JAMA 267:961-968
33. Appel GB, Blum CB, Chien S, Kunis CL, Appel AS (1985) The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure and viscosity. N Engl J Med 312:1544-1548
34. Attman PO, Alaupovic P (1991) Lipid and apolipoprotein profiles of uremic dyslipoproteinemia. Relation to renal function and dialysis. Nephron 57:401-410
35. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR (1977) High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am J Med 62:707-714
36. Castelli WP, Garrison RJ, Wilson PW, Abbot RD, Kalousdian S, Kannel WB (1986) Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham study. JAMA 256:2835-2838
37. Jacobs DR Jr, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA (1990) High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the Follow-up Study of the Lipid Research Clinics' Prevalence Study. Am J Epidemiol 131:32-47
38. Bruckdorfer KR, Hillary JB, Bunce T, Vancheeswaran R, Black CM (1995) Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis. Arthritis Rheum 38:1060-1067
39. Parthasarathy S, Barnett J, Fong LG (1990) High density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1044:275-283
40. Van Lenten BJ, Hama SY, de Beer FC et al (1995) Antiinflammatory HDL becomes pro-inflammatory during the acute phase response. J Clin Invest 96:2758-2767
41. Simonini G, Cerinic MM, Generini S et al (1999) Oxidative stress in systemic sclerosis. Mol Cell Biochem 196:85-91
42. Berliner JA, Territo MC, Sevanian A et al (1990) Minimally modified low density lipoprotein induces monocyte chemotactic protein-1 in human endothelial cells and smooth muscle cells. J Clin Invest 85:5134-5138
43. Shih PT, Elices MJ, Fang ZT et al (1999) Minimally modified low-density lipoprotein induces monocyte adhesion to endothelial connecting segment-1 by activating beta1 integrin. J Clin Invest 103:613-625
44. Bhadra S, Arshad MA, Rymaszewski Z, Norman E, Wherley R, Subbiah MT (1991) Oxidation of cholesterol moiety of low density lipoprotein in the presence of human endothelial cells or Cu + 2 ions: identification of major products and their effects. Biochem Biophys Res Commun 17:431-440
45. Herrick AL, Illingworth KJ, Hollis S, Gomez-Zumaquero JM, Tinahones FJ (2001) Antibodies against oxidized low-density lipoproteins in systemic sclerosis. Rheumatology 40:401-405
46. Lopes-Virella M, Binzafar N, Rackey S, Takei A, La Via M, Virella G (1997) The uptake of LDL-IC by human macrophages: predominant involvement of the Fc gamma RI receptor. Atherosclerosis 135:161-170
47. Borba EF, Bonfá E (2001) Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 28:780-785
48. Munro R, Morrison E, McDonald AG, Hunter JA, Madhok R, Capell HA (1997) Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis 56:374-377